Table 1.
Characteristics of eligible studies in this meta-analysis.
| First author | Year | Cancer type | Country | Sample size | Number of OE | Clinical stage/ tumor grade | Criterion of OE | Test methods | Outcome measures | MVA | NOS score | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zlobec et al 10 | 2010 | CRC | Switzerland | 87 | 36 | NA | diffuse cytoplasmic TOPK staining in >90% of colorectal tumor cells | IHC | OS | Yes | 6 | |
| He et al 11 | 2010 | CCA | China | 24 | 11 | tumor grade 1-2-3 | > the percentages of TOPK-positive cells (10 %) | IHC | OS | Yes | 6 | |
| Wei et al 12 | 2012 | LAC | China | 203 | 136 | I | IHC score >3 | IHC | OS, RFS | Yes | 7 | |
| Shih et al 18 | 2012 | LC | China | 119 | 72 | I-II-III-IV | IHC score (2, 3) | IHC | OS, DFS | Yes | 6 | |
| Lei et al 19 | 2013 | NSCLC | China | 279 | 125 | I-II-III-IV | > the median percentage of positively stained cells ( 11.5%) | IHC | OS | Yes | 8 | |
| O Leary et al 20 | 2013 | BC | Ireland | 290 | 104 | tumor grade 1-2-3 | percentage of cells stained multiplied by intensity score >48 | IHC | OS, RFS | Yes | 8 | |
| Lei et al 21 | 2015 | LAC | China | 127 | 67 | I-II-III-IV | > the average percentages of TOPK-positive cells (13.3%) | IHC | OS | Yes | 7 | |
| Chen et al 14 | 2015 | PCa | China | 98 | NA | NA | immunoreactivity scores (IRS) | IHC | OS | No | 6 | |
| Xiao et al 22 | 2015 | CRC | China | 186 | 135 | tumor grade 1-2-3 | IHC score >3 | IHC | OS, DFS | Yes | 7 | |
| Chang et al 17 | 2016 | OSCC | China | 287 | 75 | I-II-III-IV | mean PBK/TOPK expression score | IHC | OS | Yes | 7 | |
| Ikeda et al 16 | 2016 | EOC | Japan | 163 | 84 | I-II-III-IV | 2+, 3++ | IHC | OS, PFS | No | 7 | |
| Ohashi et al 23 | 2016 | ESCC | Japan | 54 | 10 | 0-I-II-III-IV | intensity plus proportion scores ≥5 | IHC | OS | Yes | 6 | |
| Wang et al 24 | 2016 | NPC | China | 185 | 92 | NA | NA | IHC | OS, DFS | Yes | 7 | |
| Zou et al 25 | 2017 | CRC | China | 80 | 43 | NA | NA | IHC | OS | No | 6 | |
| Kwon et al 15 | 2017 | GC | Korea | 385 | 79 | I-II-III | +,++ | IHC | OS | Yes | 8 | |
| Su et al 26 | 2017 | GC | China | 79 | 73 | I-II-III-IV | +,++,+++,++++ | IHC | OS | No | 6 | |
| Ohashi et al 27 | 2017 | GC | Japan | 144 | 24 | I-II-III | PBK/TOPK presenting scores ⩾5 tumor cells | IHC | OS | Yes | 7 | |
| Pirovano et al 28 | 2017 | PCa | UK | 128 | NA | NA | > the median score of PBK IHC score | IHC | OS, RFS | Yes | 7 | |
| Yang et al 29 | 2017 | HCC | China | 520 | 292 | I-II-III-IV | > the median score of PBK IHC | IHC | OS, DFS | Yes | 8 | |
| Hayashi et al 13 | 2018 | Glioma | Japan | 32 | 23 | II--III-IV | > median percentage of TOPK-positive cells (12.7%) | IHC | OS, PFS | Yes | 6 |
CRC: colorectal cancer; CCA: cholangiocarcinoma; LAC: lung adenocarcinoma; LC: lung cancer; NSCLC: non-small-cell lung cancer; BC: breast cancer; PCa: prostate cancer; OSCC: oral squamous cell carcinoma; EOC: epithelial ovarian cancer; ESCC: esophageal squamous cell carcinoma; NPC: nasopharyngeal carcinoma; GC: gastric cancer; HCC: hepatocellular carcinoma; IHC: immunohistochemistry; OS: overall survival; RFS: recurrence-free survival; PFS: progression-free survival; DFS: disease-free survival; OE: over-expression; MVA: multivariate analysis NA: not available.